{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:48:19Z","timestamp":1794970099305,"version":"4.9.1"},"reference-count":318,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"NSFC-Liaoning joint fund key program","award":["No. U20A20413, China"],"award-info":[{"award-number":["No. U20A20413, China"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"name":"Liaoning Province Scientific Research Foundation","award":["2023JH2\/20200126"],"award-info":[{"award-number":["2023JH2\/20200126"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC, No. 81903658, 82272797, 82304564, China"],"award-info":[{"award-number":["NSFC, No. 81903658, 82272797, 82304564, China"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01704-3","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:03:24Z","timestamp":1746075804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":344,"title":["Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals"],"prefix":"10.1186","volume":"18","author":[{"given":"Ruili","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongxia","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"11","key":"1704_CR1","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s11427-022-2240-6","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yan Q, Fan C, Mo Y, Wang Y, Li X, et al. Overview and countermeasures of cancer burden in China. Sci China Life. 2023;66(11):2515\u201326.","journal-title":"Sci China Life"},{"issue":"3","key":"1704_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung HYA, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Ca-Cancer J Clin"},{"issue":"4","key":"1704_CR3","doi-asserted-by":"publisher","first-page":"101211","DOI":"10.1016\/j.gendis.2024.101211","volume":"11","author":"U Anand","year":"2024","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2024;11(4):101211.","journal-title":"Genes Dis"},{"key":"1704_CR4","doi-asserted-by":"publisher","first-page":"215969","DOI":"10.1016\/j.canlet.2022.215969","volume":"552","author":"YQ Yang","year":"2023","unstructured":"Yang YQ, Wang SH, Ma PW, Jiang YL, Cheng KM, Yu Y, et al. Drug conjugate-based anticancer therapy-current status and perspectives. Cancer Lett. 2023;552:215969.","journal-title":"Cancer Lett"},{"issue":"6162","key":"1704_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323a0","volume":"332","author":"L Riechmann","year":"1988","unstructured":"Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332(6162):323\u20137.","journal-title":"Nature"},{"issue":"1","key":"1704_CR6","doi-asserted-by":"publisher","first-page":"2373330","DOI":"10.1080\/19420862.2024.2373330","volume":"16","author":"B Kelley","year":"2024","unstructured":"Kelley B. The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras. MAbs. 2024;16(1):2373330.","journal-title":"MAbs"},{"key":"1704_CR7","doi-asserted-by":"publisher","first-page":"1379738","DOI":"10.3389\/fonc.2024.1379738","volume":"14","author":"MA Shapiro","year":"2024","unstructured":"Shapiro MA. Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer. Front Oncol. 2024;14:1379738.","journal-title":"Front Oncol"},{"issue":"10200","key":"1704_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793\u2013804.","journal-title":"Lancet"},{"issue":"11","key":"1704_CR9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo R, Rich JR. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell. 2022;40(11):1255\u201363.","journal-title":"Cancer Cell"},{"issue":"14","key":"1704_CR10","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-17-3179","volume":"24","author":"EY Jen","year":"2018","unstructured":"Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, et al. FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24(14):3242\u20136.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1704_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","volume":"46","author":"Y Hong","year":"2023","unstructured":"Hong Y, Nam SM, Moon A. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Arch Pharm Res. 2023;46(3):131\u201348.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1704_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1704_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","volume":"38","author":"CT Harris","year":"2024","unstructured":"Harris CT, Cohen S. Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs. 2024;38(2):205\u201326.","journal-title":"BioDrugs"},{"issue":"18 Suppl","key":"1704_CR14","first-page":"S975","volume":"6","author":"JP Williams","year":"2000","unstructured":"Williams JP, Handler HL. Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia. Am J Manag Care. 2000;6(18 Suppl):S975-985.","journal-title":"Am J Manag Care"},{"issue":"4","key":"1704_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/17474086.2014.924849","volume":"7","author":"C O'Hear","year":"2014","unstructured":"O\u2019Hear C, Rubnitz JE. Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback? Expert Rev Hematol. 2014;7(4):427\u20139.","journal-title":"Expert Rev Hematol"},{"issue":"13","key":"1704_CR16","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/cancers13133214","volume":"13","author":"M Molica","year":"2021","unstructured":"Molica M, Perrone S, Mazzone C, Niscola P, Cesini L, Abruzzese E, et al. CD33 expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin. Cancers (Basel). 2021;13(13):3214.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1704_CR17","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234(5):5628\u201342.","journal-title":"J Cell Physiol"},{"issue":"5","key":"1704_CR18","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","volume":"28","author":"X Sun","year":"2017","unstructured":"Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, et al. Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem. 2017;28(5):1371\u201381.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"1704_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1704_CR20","doi-asserted-by":"publisher","first-page":"1702262","DOI":"10.1080\/19420862.2019.1702262","volume":"12","author":"M Farr\u00e0s","year":"2020","unstructured":"Farr\u00e0s M, Miret J, Camps M, Rom\u00e1n R, Mart\u00ednez O, Pujol X, et al. Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly. MAbs. 2020;12(1):1702262.","journal-title":"MAbs"},{"issue":"7","key":"1704_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nbt.3274","volume":"33","author":"P Strop","year":"2015","unstructured":"Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol. 2015;33(7):694\u20136.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"1704_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33(7):733\u20135.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"1704_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"key":"1704_CR24","doi-asserted-by":"publisher","first-page":"1334938","DOI":"10.3389\/fonc.2023.1334938","volume":"13","author":"YZ Cheng","year":"2023","unstructured":"Cheng YZ, Yuan XX, Tian Q, Huang XY, Chen Y, Pu YZ, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front Oncol. 2023;13:1334938.","journal-title":"Front Oncol"},{"issue":"10","key":"1704_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10):1019\u201325.","journal-title":"Drugs"},{"key":"1704_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ijbiomac.2022.06.195","volume":"216","author":"IG Jiacomini","year":"2022","unstructured":"Jiacomini IG, Beltramino M, Boursin F, Minozzo JC, de Moura JF, Billiald P, et al. An effective strategy for the humanization of antibody fragments under an accelerated timeline. Int J Biol Macromol. 2022;216:465\u201374.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"1704_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt K, Ullrich A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1704_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/bjc.1983.4","volume":"47","author":"CH Ford","year":"1983","unstructured":"Ford CH, Newman CE, Johnson JR, Woodhouse CS, Reeder TA, Rowland GF, et al. Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Br J Cancer. 1983;47(1):35\u201342.","journal-title":"Br J Cancer"},{"issue":"5517","key":"1704_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495\u20137.","journal-title":"Nature"},{"issue":"3","key":"1704_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1704_CR31","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1002\/mco2.671","volume":"5","author":"J He","year":"2024","unstructured":"He J, Zeng X, Wang C, Wang E, Li Y. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm (2020). 2024;5(8):e671.","journal-title":"MedComm (2020)."},{"issue":"6","key":"1704_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111(6):538\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"1704_CR33","doi-asserted-by":"publisher","first-page":"122676","DOI":"10.1016\/j.lfs.2024.122676","volume":"347","author":"ZX Phuna","year":"2024","unstructured":"Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH. Antibody-drug conjugates: principles and opportunities. Life Sci. 2024;347:122676.","journal-title":"Life Sci"},{"issue":"7","key":"1704_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346.","journal-title":"Cancer Sci"},{"issue":"12","key":"1704_CR35","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736\u201342.","journal-title":"Br J Cancer"},{"issue":"7","key":"1704_CR36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24(7):809\u201317.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"1704_CR37","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76(9):2710\u20139.","journal-title":"Cancer Res"},{"issue":"13","key":"1704_CR38","doi-asserted-by":"publisher","first-page":"e2306309","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo Y, Shen Z, Zhao W, Lu J, Song Y, Shen L, et al. Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv Sci (Weinh). 2024;11(13):e2306309.","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"1704_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/antib9040064","volume":"9","author":"R Liu","year":"2020","unstructured":"Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies (Basel). 2020;9(4):64.","journal-title":"Antibodies (Basel)"},{"issue":"2","key":"1704_CR40","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.3324\/haematol.2017.178996","volume":"103","author":"S Herter","year":"2018","unstructured":"Herter S, Herting F, Muth G, van Puijenbroek E, Schlothauer T, Ferrara C, et al. GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. Haematologica. 2018;103(2):E78\u201381.","journal-title":"Haematologica"},{"key":"1704_CR41","first-page":"13","volume":"423","author":"RF Graziano","year":"2019","unstructured":"Graziano RF, Engelhardt JJ. Role of Fc\u03b3Rs in antibody-based cancer therapy. Curr Top Microbiol. 2019;423:13\u201334.","journal-title":"Curr Top Microbiol"},{"issue":"19","key":"1704_CR42","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.3390\/jcm13195815","volume":"13","author":"C Henriques","year":"2024","unstructured":"Henriques C, da Ana R, Krambeck K, Miguel S, Santini A, Zielinska A, et al. Monoclonal antibodies for the treatment of ocular diseases. J Clin Med. 2024;13(19):5815.","journal-title":"J Clin Med"},{"issue":"16","key":"1704_CR43","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.3390\/ijms22168947","volume":"22","author":"P Gogesch","year":"2021","unstructured":"Gogesch P, Dudek S, van Zandbergen G, Waibler Z, Anzaghe M. The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies. Int J Mol Sci. 2021;22(16):8947.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1704_CR44","doi-asserted-by":"publisher","first-page":"e00225","DOI":"10.1042\/BSR20150089","volume":"35","author":"C Peters","year":"2015","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Rep. 2015;35(4):e00225.","journal-title":"Bioscience Rep"},{"key":"1704_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jconrel.2018.06.016","volume":"284","author":"R Tsumura","year":"2018","unstructured":"Tsumura R, Manabe S, Takashima H, Koga Y, Yasunaga M, Matsumura Y. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J Control Release. 2018;284:49\u201356.","journal-title":"J Control Release"},{"issue":"4","key":"1704_CR46","doi-asserted-by":"publisher","first-page":"e0293703","DOI":"10.1371\/journal.pone.0293703","volume":"19","author":"A Datta-Mannan","year":"2024","unstructured":"Datta-Mannan A, Choi H, Jin ZY, Liu L, Lu JR, Stokell DJ, et al. Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals. PLoS One. 2024;19(4):e0293703.","journal-title":"PLoS One"},{"key":"1704_CR47","doi-asserted-by":"publisher","first-page":"155627","DOI":"10.1016\/j.prp.2024.155627","volume":"263","author":"AZA Asmani","year":"2024","unstructured":"Asmani AZA, Zainuddin AFF, Azmi Murad NA, Mohd Darwis NH, Suhaimi NS, Zaini E, et al. Immunogenicity of monoclonal antibody: causes, consequences, and control strategies. Pathol Res Pract. 2024;263:155627.","journal-title":"Pathol Res Pract"},{"issue":"12","key":"1704_CR48","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1021\/acs.chemrev.2c00915","volume":"123","author":"LH Qian","year":"2023","unstructured":"Qian LH, Lin XF, Gao X, Khan RU, Liao JY, Du SB, et al. The dawn of a New Era: targeting the \u201cUndruggables\u201d with antibody-based therapeutics. Chem Rev. 2023;123(12):7782\u2013853.","journal-title":"Chem Rev"},{"key":"1704_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1600-065X.1998.tb01188.x","volume":"163","author":"R Jefferis","year":"1998","unstructured":"Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev. 1998;163:59\u201376.","journal-title":"Immunol Rev"},{"issue":"20","key":"1704_CR50","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","volume":"25","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020;25(20):4764.","journal-title":"Molecules"},{"issue":"1","key":"1704_CR51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/pharmaceutics15010187","volume":"15","author":"C Yang","year":"2023","unstructured":"Yang C, He B, Zhang H, Wang X, Zhang Q, Dai W. IgG Fc affinity ligands and their applications in antibody-involved drug delivery: a brief review. Pharmaceutics. 2023;15(1):187.","journal-title":"Pharmaceutics"},{"key":"1704_CR52","doi-asserted-by":"publisher","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.\u00a0https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","DOI":"10.1038\/s41392-022-00947-7"},{"issue":"2","key":"1704_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd3365","volume":"10","author":"XR Jiang","year":"2011","unstructured":"Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discovery. 2011;10(2):101\u201310.","journal-title":"Nat Rev Drug Discovery"},{"issue":"7","key":"1704_CR54","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14712598.2021.1880562","volume":"21","author":"M De Cecco","year":"2021","unstructured":"De Cecco M, Galbraith DN, McDermott LL. What makes a good antibody-drug conjugate? Expert Opin Biol Ther. 2021;21(7):841\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1704_CR55","doi-asserted-by":"publisher","first-page":"14820","DOI":"10.1038\/s41598-018-32986-y","volume":"8","author":"A Clavero-Alvarez","year":"2018","unstructured":"Clavero-Alvarez A, Di Mambro T, Perez-Gaviro S, Magnani M, Bruscolini P. Humanization of antibodies using a statistical inference approach. Sci Rep. 2018;8(1):14820.","journal-title":"Sci Rep"},{"issue":"4","key":"1704_CR56","doi-asserted-by":"publisher","first-page":"e0195823","DOI":"10.1371\/journal.pone.0195823","volume":"13","author":"P Herbener","year":"2018","unstructured":"Herbener P, Schonfeld K, Konig M, Germer M, Przyborski JM, Bernoster K, et al. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. PLoS One. 2018;13(4):e0195823.","journal-title":"PLoS One"},{"issue":"4","key":"1704_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1704_CR58","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/biomedicines12030500","volume":"12","author":"G Saltalamacchia","year":"2024","unstructured":"Saltalamacchia G, Torrisi R, De Sanctis R, Masci G, Miggiano C, Gaudio M, et al. Charting the course in sequencing antibody-drug conjugates in breast cancer. Biomedicines. 2024;12(3):500.","journal-title":"Biomedicines"},{"issue":"7","key":"1704_CR59","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1158\/1538-7445.AM2023-2633","volume":"83","author":"SD Barnscher","year":"2023","unstructured":"Barnscher SD, Rojas AH, Hamblett KJ, Escalante N. Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer. Can Res. 2023;83(7):2633.","journal-title":"Can Res"},{"issue":"5","key":"1704_CR60","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: making 1+1>2. Acta Pharm Sin B. 2024;14(5):1965\u201386.","journal-title":"Acta Pharm Sin B"},{"key":"1704_CR61","doi-asserted-by":"publisher","unstructured":"Song EW, Yao HR, Sun ML, Zong H, Lin RB, Zou W et al. BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive\/low-expression and other solid tumors: Results from a first-in-human phase 1 study. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-PO2-04-03.","DOI":"10.1158\/1538-7445.SABCS23-PO2-04-03"},{"key":"1704_CR62","doi-asserted-by":"publisher","unstructured":"Zhang L, Ma YX, Zhao YY, Fang WF, Zhao HY, Huang Y et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. J Clin Oncol. 2023. https:\/\/doi.org\/10.1080\/1750743X.2024.2359359.","DOI":"10.1080\/1750743X.2024.2359359"},{"issue":"4","key":"1704_CR63","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11684-024-1072-8","volume":"18","author":"H Zeng","year":"2024","unstructured":"Zeng H, Ning W, Liu X, Luo W, Xia N. Unlocking the potential of bispecific ADCs for targeted cancer therapy. Front Med. 2024;18(4):597\u2013621.","journal-title":"Front Med"},{"issue":"6","key":"1704_CR64","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/cancers15061845","volume":"15","author":"B Esapa","year":"2023","unstructured":"Esapa B, Jiang JX, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN. Target antigen attributes and their contributions to clinically approved Antibody-Drug Conjugates (ADCs) in haematopoietic and solid cancers. Cancers. 2023;15(6):1845.","journal-title":"Cancers"},{"issue":"11","key":"1704_CR65","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","volume":"32","author":"M Damelin","year":"2015","unstructured":"Damelin M, Zhong W, Myers J, Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32(11):3494\u2013507.","journal-title":"Pharm Res"},{"key":"1704_CR66","doi-asserted-by":"publisher","first-page":"101086","DOI":"10.1016\/j.drup.2024.101086","volume":"75","author":"M Jiang","year":"2024","unstructured":"Jiang M, Li Q, Xu B. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement. Drug Resist Updat. 2024;75:101086.","journal-title":"Drug Resist Updat"},{"issue":"4","key":"1704_CR67","doi-asserted-by":"publisher","first-page":"101224","DOI":"10.1016\/j.beha.2020.101224","volume":"33","author":"MC Clark","year":"2020","unstructured":"Clark MC, Stein A. CD33 directed bispecific antibodies in acute myeloid leukemia. Best Pract Res Clin Haematol. 2020;33(4):101224.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"1704_CR68","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1158\/1535-7163.MCT-23-0720","volume":"23","author":"T Satomaa","year":"2024","unstructured":"Satomaa T, Pynnonen H, Aitio O, Hiltunen JO, Pitkanen V, Lahteenmaki T, et al. Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window. Mol Cancer Ther. 2024;23(8):1073\u201383.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1704_CR69","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14712598.2021.1825678","volume":"21","author":"BH Goldenson","year":"2021","unstructured":"Goldenson BH, Goodman AM, Ball ED. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Th. 2021;21(7):849\u201362.","journal-title":"Expert Opin Biol Th"},{"issue":"7","key":"1704_CR70","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/ph14070674","volume":"14","author":"M Hammood","year":"2021","unstructured":"Hammood M, Craig AW, Leyton JV. Impact of endocytosis mechanisms for the receptors targeted by the currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC research and development. Pharmaceuticals-Base. 2021;14(7):674.","journal-title":"Pharmaceuticals-Base"},{"issue":"9","key":"1704_CR71","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"CA Van der Weyden","year":"2017","unstructured":"Van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1704_CR72","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/PAS.0000000000001368","volume":"44","author":"ML Xu","year":"2020","unstructured":"Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, et al. Practical approaches on CD30 detection and reporting in lymphoma diagnosis. Am J Surg Pathol. 2020;44(2):e1\u201314.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"1704_CR73","doi-asserted-by":"publisher","first-page":"8731","DOI":"10.3390\/ijms24108731","volume":"24","author":"M Nakashima","year":"2023","unstructured":"Nakashima M, Uchimaru K. CD30 expression and its functions during the disease progression of adult T-cell leukemia\/lymphoma. Int J Mol Sci. 2023;24(10):8731.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1704_CR74","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","volume":"14","author":"K Karube","year":"2021","unstructured":"Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol. 2021;14(8):777\u201387.","journal-title":"Expert Rev Hematol"},{"key":"1704_CR75","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1600-065X.2009.00801.x","volume":"230","author":"L Nitschke","year":"2009","unstructured":"Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 2009;230:128\u201343.","journal-title":"Immunol Rev"},{"issue":"7","key":"1704_CR76","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nrrheum.2014.54","volume":"10","author":"J Muller","year":"2014","unstructured":"Muller J, Nitschke L. The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol. 2014;10(7):422\u20138.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1704_CR77","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/ijms22042150","volume":"22","author":"M Martino","year":"2021","unstructured":"Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 2021;22(4):2150.","journal-title":"Int J Mol Sci"},{"key":"1704_CR78","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"15","key":"1704_CR79","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","volume":"68","author":"X Du","year":"2008","unstructured":"Du X, Beers R, FitzGerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity. Can Res. 2008;68(15):6300\u20135.","journal-title":"Can Res"},{"issue":"1","key":"1704_CR80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms25010010","volume":"25","author":"A Tkachenko","year":"2023","unstructured":"Tkachenko A, Kupcova K, Havranek O. B-Cell receptor signaling and beyond: the role of Igalpha (CD79a)\/Igbeta (CD79b) in normal and malignant B cells. Int J Mol Sci. 2023;25(1):10.","journal-title":"Int J Mol Sci"},{"key":"1704_CR81","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.fsi.2019.01.012","volume":"87","author":"L Wu","year":"2019","unstructured":"Wu L, Bian X, Kong L, Yin X, Mu L, Wu S, et al. B cell receptor accessory molecule CD79 gets involved in response against Streptococcus agalactiae infection and BCR signaling in Nile tilapia (Oreochromis niloticus). Fish Shellfish Immunol. 2019;87:212\u20139.","journal-title":"Fish Shellfish Immunol"},{"issue":"2","key":"1704_CR82","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00022744-200106000-00001","volume":"9","author":"PG Chu","year":"2001","unstructured":"Chu PG, Arber DA. CD79: a review. Appl Immunohisto M M. 2001;9(2):97\u2013106.","journal-title":"Appl Immunohisto M M"},{"issue":"12","key":"1704_CR83","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/cancers16122243","volume":"16","author":"F D'Alo","year":"2024","unstructured":"D\u2019Alo F, Bellesi S, Maiolo E, Alma E, Bellisario F, Malafronte R, et al. Novel targets and advanced therapies in diffuse large B cell lymphomas. Cancers (Basel). 2024;16(12):2243.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1704_CR84","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3892\/ol.2017.6528","volume":"14","author":"J Pan","year":"2017","unstructured":"Pan J, Sun Y, Zhang N, Li J, Ta F, Wei W, et al. Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol Lett. 2017;14(3):2657\u201362.","journal-title":"Oncol Lett"},{"issue":"1","key":"1704_CR85","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1704_CR86","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36.","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"1704_CR87","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41590-022-01314-y","volume":"23","author":"MT Witkowski","year":"2022","unstructured":"Witkowski MT, Lee S, Wang E, et al. NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nat Immunol. 2022;23(10):1424\u201332.","journal-title":"Nat Immunol"},{"issue":"4","key":"1704_CR88","first-page":"303","volume":"140","author":"E Calabretta","year":"2022","unstructured":"Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. Blood. 2022;140(4):303\u20138.","journal-title":"Blood"},{"issue":"1","key":"1704_CR89","doi-asserted-by":"publisher","first-page":"1859049","DOI":"10.1080\/19420862.2020.1859049","volume":"13","author":"P Bhatta","year":"2021","unstructured":"Bhatta P, Whale KD, Sawtell AK, Thompson CL, Rapecki SE, Cook DA, et al. Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries. MAbs. 2021;13(1):1859049.","journal-title":"MAbs"},{"issue":"10","key":"1704_CR90","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem. 2020;20(10):815\u201334.","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"1704_CR91","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499\u2013514.","journal-title":"Nat Rev Clin Oncol"},{"key":"1704_CR92","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u201375.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1704_CR93","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","volume":"284","author":"RN Jorissen","year":"2003","unstructured":"Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31\u201353.","journal-title":"Exp Cell Res"},{"issue":"1","key":"1704_CR94","doi-asserted-by":"publisher","first-page":"e001492","DOI":"10.1136\/bmjresp-2022-001492","volume":"10","author":"U Batra","year":"2023","unstructured":"Batra U, Biswas B, Prabhash K, Krishna MV. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ Open Respir Res. 2023;10(1):e001492.","journal-title":"BMJ Open Respir Res"},{"issue":"8","key":"1704_CR95","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41556-022-00962-4","volume":"24","author":"G Guo","year":"2022","unstructured":"Guo G, Gong K, Beckley N, et al. EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation. Nat Cell Biol. 2022;24(8):1291\u2013305.","journal-title":"Nat Cell Biol"},{"issue":"17","key":"1704_CR96","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","volume":"24","author":"S Kalyankrishna","year":"2006","unstructured":"Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666\u201372.","journal-title":"J Clin Oncol"},{"key":"1704_CR97","doi-asserted-by":"publisher","first-page":"120082","DOI":"10.1016\/j.ijpharm.2020.120082","volume":"592","author":"EDS Santos","year":"2021","unstructured":"Santos EDS, Nogueira KAB, Fernandes LCC, et al. EGFR targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm. 2021;592:120082.","journal-title":"Int J Pharm"},{"issue":"6","key":"1704_CR98","first-page":"739","volume":"11","author":"R Kwapiszewski","year":"2016","unstructured":"Kwapiszewski R, Pawlak SD, Adamkiewicz K. Anti-EGFR agents: current status, forecasts and future directions. target. Oncol. 2016;11(6):739\u201352.","journal-title":"Oncol"},{"key":"1704_CR99","doi-asserted-by":"publisher","first-page":"e53934","DOI":"10.7554\/eLife.53934","volume":"9","author":"B Choi","year":"2020","unstructured":"Choi B, Cha M, Eun GS, Lee DH, Lee S, Ehsan M, et al. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. Elife. 2020;9:e53934.","journal-title":"Elife"},{"issue":"7","key":"1704_CR100","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes (Basel). 2024;15(7):903.","journal-title":"Genes (Basel)"},{"key":"1704_CR101","doi-asserted-by":"publisher","first-page":"103997","DOI":"10.1016\/j.critrevonc.2023.103997","volume":"186","author":"M Galogre","year":"2023","unstructured":"Galogre M, Rodin D, Pyatnitskiy M, Mackelprang M, Koman I. A review of HER2 overexpression and somatic mutations in cancers. Crit Rev Oncol Hematol. 2023;186:103997.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1704_CR102","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.","journal-title":"Mol Biol Int"},{"issue":"1","key":"1704_CR103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1704_CR104","first-page":"188488","volume":"1874","author":"V Akbari","year":"2020","unstructured":"Akbari V, Chou CP, Abedi D. New insights into affinity proteins for HER2-targeted therapy: beyond trastuzumab. Bba-Rev Cancer. 2020;1874(2):188488.","journal-title":"Bba-Rev Cancer"},{"issue":"3","key":"1704_CR105","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10120-021-01164-x","volume":"24","author":"M Aoki","year":"2021","unstructured":"Aoki M, Iwasa S, Boku N. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer. 2021;24(3):567\u201376.","journal-title":"Gastric Cancer"},{"issue":"11","key":"1704_CR106","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/cancers12113328","volume":"12","author":"S Len\u00e1rt","year":"2020","unstructured":"Len\u00e1rt S, Len\u00e1rt P, Smarda J, Rems\u00edk J, Soucek K, Benes P. Trop2: jack of all trades, master of none. Cancers. 2020;12(11):3328.","journal-title":"Cancers"},{"key":"1704_CR107","doi-asserted-by":"publisher","first-page":"108336","DOI":"10.1016\/j.pharmthera.2022.108336","volume":"243","author":"X Liu","year":"2023","unstructured":"Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang Y, et al. Corrigendum to \u201cAdvances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer\u201d [Pharmacology & Therapeutics 239 (2022) 108296]. Pharmacol Ther. 2023;243:108336.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1704_CR108","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1186\/s12885-022-10076-7","volume":"22","author":"Y Jeon","year":"2022","unstructured":"Jeon Y, Jo U, Hong J, Gong G, Lee HJ. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer. 2022;22(1):1014.","journal-title":"BMC Cancer"},{"issue":"4","key":"1704_CR109","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00018-014-1763-4","volume":"72","author":"D Samanta","year":"2015","unstructured":"Samanta D, Almo SC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci. 2015;72(4):645\u201358.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"1704_CR110","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/ijo.2021.5273","volume":"59","author":"Y Liu","year":"2021","unstructured":"Liu Y, Han X, Li L, Zhang Y, Huang X, Li G, et al. Role of Nectin-4 protein in cancer (Review). Int J Oncol. 2021;59(5):93.","journal-title":"Int J Oncol"},{"issue":"2","key":"1704_CR111","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","volume":"18","author":"EI Heath","year":"2021","unstructured":"Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93\u2013103.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1704_CR112","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11239-022-02662-0","volume":"54","author":"H Li","year":"2022","unstructured":"Li H, Yu Y, Gao L, Zheng P, Liu X, Chen H. Tissue factor: a neglected role in cancer biology. J Thromb Thrombolysis. 2022;54(1):97\u2013108.","journal-title":"J Thromb Thrombolysis"},{"key":"1704_CR113","doi-asserted-by":"publisher","first-page":"101781","DOI":"10.1016\/j.smim.2023.101781","volume":"69","author":"SO Vasudevan","year":"2023","unstructured":"Vasudevan SO, Behl B, Rathinam VA. Pyroptosis-induced inflammation and tissue damage. Semin Immunol. 2023;69:101781.","journal-title":"Semin Immunol"},{"issue":"1","key":"1704_CR114","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40364-023-00504-6","volume":"11","author":"SE Ahmadi","year":"2023","unstructured":"Ahmadi SE, Shabannezhad A, Kahrizi A, Akbar A, Safdari SM, Hoseinnezhad T, et al. Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer. Biomark Res. 2023;11(1):60.","journal-title":"Biomark Res"},{"issue":"2","key":"1704_CR115","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/ijms25021046","volume":"25","author":"T Gonzalez","year":"2024","unstructured":"Gonzalez T, Muminovic M, Nano O, Vulfovich M. Folate receptor Alpha-A novel approach to cancer therapy. Int J Mol Sci. 2024;25(2):1046.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1704_CR116","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor alpha in oncology. Nat Rev Clin Oncol. 2020;17(6):349\u201359.","journal-title":"Nat Rev Clin Oncol"},{"key":"1704_CR117","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","volume":"170","author":"L Gilbert","year":"2023","unstructured":"Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023;170:241\u20137.","journal-title":"Gynecol Oncol"},{"issue":"22","key":"1704_CR118","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1039\/D2CS00446A","volume":"51","author":"N Ashman","year":"2022","unstructured":"Ashman N, Bargh JD, Spring DR. Non-internalising antibody-drug conjugates. Chem Soc Rev. 2022;51(22):9182\u2013202.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"1704_CR119","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33\u201346.","journal-title":"Protein Cell"},{"issue":"2","key":"1704_CR120","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"R Sheyi","year":"2022","unstructured":"Sheyi R, de la Torre BG, Albericio F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics. 2022;14(2):396.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1704_CR121","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1021\/acs.bioconjchem.1c00029","volume":"32","author":"S Chuprakov","year":"2021","unstructured":"Chuprakov S, Ogunkoya AO, Barfield RM, Bauzon M, Hickle C, Kim YC, et al. Tandem-cleavage linkers improve the in vivo stability and tolerability of antibody-drug conjugates. Bioconjug Chem. 2021;32(4):746\u201354.","journal-title":"Bioconjug Chem"},{"issue":"16","key":"1704_CR122","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48(16):4361\u201374.","journal-title":"Chem Soc Rev"},{"key":"1704_CR123","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-62703-541-5_5","volume":"1045","author":"B Nolting","year":"2013","unstructured":"Nolting B. Linker technologies for antibody-drug conjugates. Methods Mol Biol. 2013;1045:71\u2013100.","journal-title":"Methods Mol Biol"},{"issue":"11","key":"1704_CR124","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"EL Sievers","year":"1999","unstructured":"Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678\u201384.","journal-title":"Blood"},{"issue":"8","key":"1704_CR125","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/10428194.2020.1742897","volume":"61","author":"ES Wang","year":"2020","unstructured":"Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, et al. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2020;61(8):1965\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1704_CR126","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807\u201314.","journal-title":"Blood"},{"issue":"1","key":"1704_CR127","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1078-0432.CCR-05-1905","volume":"12","author":"JF DiJoseph","year":"2006","unstructured":"DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin\u2019s B-cell lymphoma. Clin Cancer Res. 2006;12(1):242\u20139.","journal-title":"Clin Cancer Res"},{"key":"1704_CR128","doi-asserted-by":"publisher","unstructured":"Tolaney SM, Cardillo TM, Chou CC, Dornan C, Faris M. The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors. Clin Cancer Res. Published online February 4, 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1525.","DOI":"10.1158\/1078-0432.CCR-24-1525"},{"key":"1704_CR129","doi-asserted-by":"publisher","first-page":"130085","DOI":"10.1016\/j.bmcl.2024.130085","volume":"118","author":"GR Mathi","year":"2025","unstructured":"Mathi GR, Lee BS, Chun Y, et al. Design, synthesis and biological evaluation of camptothecin analogue FL118 as a payload for antibody-drug conjugates in targeted cancer therapy. Bioorg Med Chem Lett. 2025;118:130085.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"1704_CR130","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741\u201351.","journal-title":"N Engl J Med"},{"key":"1704_CR131","doi-asserted-by":"publisher","first-page":"116699","DOI":"10.1016\/j.ejmech.2024.116699","volume":"276","author":"A Nazli","year":"2024","unstructured":"Nazli A, Irshad Khan MZ, Racz A, Beni S. Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release. Eur J Med Chem. 2024;276:116699.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1704_CR132","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1039\/C6SC01831A","volume":"8","author":"TH Pillow","year":"2017","unstructured":"Pillow TH, Sadowsky JD, Zhang D, et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci. 2017;8(1):366\u201370.","journal-title":"Chem Sci"},{"key":"1704_CR133","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.2147\/IJN.S471734","volume":"19","author":"W Ma","year":"2024","unstructured":"Ma W, Wang X, Zhang D, Mu X. Research progress of disulfide bond based tumor microenvironment targeted drug delivery system. Int J Nanomedicine. 2024;19:7547\u201366.","journal-title":"Int J Nanomedicine"},{"issue":"22","key":"1704_CR134","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1016\/j.bmc.2016.09.043","volume":"24","author":"B Li","year":"2016","unstructured":"Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, et al. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg Med Chem. 2016;24(22):5855\u201360.","journal-title":"Bioorg Med Chem"},{"key":"1704_CR135","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 53248044, 1- (2,5-Dioxopyrrolidin-1-yloxy) -1-oxo-4- (pyridin-2-yldisulfanyl) butane-2-sulfonic acid. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/53248044. Accessed 23 May 2024."},{"issue":"6","key":"1704_CR136","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1021\/acs.molpharmaceut.5b00175","volume":"12","author":"EE Hong","year":"2015","unstructured":"Hong EE, Erickson H, Lutz RJ, Whiteman KR, Jones G, Kovtun Y, et al. Design of coltuximab ravtansine, a CD19-targeting Antibody-Drug Conjugate (ADC) for the treatment of B-cell malignancies: structure-activity relationships and preclinical evaluation. Mol Pharm. 2015;12(6):1703\u201316.","journal-title":"Mol Pharm"},{"key":"1704_CR137","doi-asserted-by":"publisher","unstructured":"Ma F, Qiu FM, Tong ZS, Wang JN, Tan YN, Bai R, et al. Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced\/ metastatic solid tumors. J Clin Oncol. 2023;41(16). https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.1100.","DOI":"10.1200\/JCO.2023.41.16_suppl.1100"},{"issue":"6","key":"1704_CR138","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757\u201365.","journal-title":"Ann Oncol"},{"key":"1704_CR139","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 57544445, MC-Val-Cit-PABA. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/MC-Val-Cit-PABA. Accessed 25 Nov 2024."},{"issue":"11","key":"1704_CR140","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/biomedicines11113080","volume":"11","author":"S Balamkundu","year":"2023","unstructured":"Balamkundu S, Liu CF. Lysosomal-cleavable peptide linkers in antibody-drug conjugates. Biomedicines. 2023;11(11):3080.","journal-title":"Biomedicines"},{"issue":"3","key":"1704_CR141","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11095-023-03649-z","volume":"41","author":"M Li","year":"2024","unstructured":"Li M, Zhao X, Yu C, Wang L. Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy. Pharm Res. 2024;41(3):419\u201340.","journal-title":"Pharm Res"},{"issue":"3","key":"1704_CR142","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/bc0600214","volume":"17","author":"SC Jeffrey","year":"2006","unstructured":"Jeffrey SC, Andreyka JB, Bernhardt SX, et al. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug Chem. 2006;17(3):831\u201340.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"1704_CR143","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: recent advances in linker chemistry. Acta Pharm Sin B. 2021;11(12):3889\u2013907.","journal-title":"Acta Pharm Sin B"},{"issue":"19","key":"1704_CR144","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-08-0916","volume":"14","author":"E Oflazoglu","year":"2008","unstructured":"Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an non-cleavable linker. Clin Cancer Res. 2008;14(19):6171\u201380.","journal-title":"Clin Cancer Res"},{"key":"1704_CR145","doi-asserted-by":"publisher","first-page":"687926","DOI":"10.3389\/fphar.2021.687926","volume":"12","author":"DA Su","year":"2021","unstructured":"Su DA, Zhang DL. Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy modulating the stability and payload release efficiency. Front Pharmacol. 2021;12:687926.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1704_CR146","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/ph14050442","volume":"14","author":"V Kostova","year":"2021","unstructured":"Kostova V, Desos P, Starck JB, Kotschy A. The chemistry behind ADCs. Pharmaceuticals (Basel). 2021;14(5):442.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"1704_CR147","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1158\/1078-0432.CCR-19-3980","volume":"26","author":"S Wedam","year":"2020","unstructured":"Wedam S, Fashoyin-Aje L, Gao X, Bloomquist E, Tang S, Sridhara R, et al. FDA Approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res. 2020;26(16):4180\u20135.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1704_CR148","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","volume":"6","author":"S Garcia-Alonso","year":"2020","unstructured":"Garcia-Alonso S, Ocana A, Pandiella A. Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond. Trends Cancer. 2020;6(2):130\u201346.","journal-title":"Trends Cancer"},{"issue":"15","key":"1704_CR149","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Belantamab mafodotin: first approval. Drugs. 2020;80(15):1607\u201313.","journal-title":"Drugs"},{"issue":"1","key":"1704_CR150","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1021\/acs.jmedchem.0c01530","volume":"64","author":"M Alas","year":"2021","unstructured":"Alas M, Saghaeidehkordi A, Kaur K. Peptide-drug conjugates with different linkers for cancer therapy. J Med Chem. 2021;64(1):216\u201332.","journal-title":"J Med Chem"},{"issue":"9","key":"1704_CR151","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1021\/acs.molpharmaceut.9b00529","volume":"16","author":"NC Yoder","year":"2019","unstructured":"Yoder NC, Bai C, Tavares D, Widdison WC, Whiteman KR, Wilhelm A, et al. A case study comparing heterogeneous lysine- and site-specific cysteine-conjugated maytansinoid Antibody-Drug Conjugates (ADCs) illustrates the benefits of lysine conjugation. Mol Pharm. 2019;16(9):3926\u201337.","journal-title":"Mol Pharm"},{"issue":"7","key":"1704_CR152","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/14712598.2021.1846714","volume":"21","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Mendelsohn BA. An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opin Biol Ther. 2021;21(7):963\u201375.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"1704_CR153","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1021\/acs.bioconjchem.1c00213","volume":"32","author":"J You","year":"2021","unstructured":"You J, Zhang J, Wang J, Jin M. Cysteine-based coupling: challenges and solutions. Bioconjug Chem. 2021;32(8):1525\u201334.","journal-title":"Bioconjug Chem"},{"issue":"Suppl 1","key":"1704_CR154","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10875-016-0265-6","volume":"36","author":"D Schumacher","year":"2016","unstructured":"Schumacher D, Hackenberger CP, Leonhardt H, Helma J. Current status: site-specific antibody drug conjugates. J Clin Immunol. 2016;36(Suppl 1):100\u20137.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1704_CR155","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1021\/acs.bioconjchem.7b00791","volume":"29","author":"R Ohri","year":"2018","unstructured":"Ohri R, Bhakta S, Fourie-O\u2019Donohue A, Dela Cruz-Chuh J, Tsai SP, Cook R, et al. High-throughput cysteine scanning to identify stable antibody conjugation sites for maleimide- and disulfide-based linkers. Bioconjug Chem. 2018;29(2):473\u201385.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"1704_CR156","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/cancers16020447","volume":"16","author":"V Metrangolo","year":"2024","unstructured":"Metrangolo V, Engelholm LH. Antibody-drug conjugates: the dynamic evolution from conventional to next-generation constructs. Cancers (Basel). 2024;16(2):447.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1704_CR157","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41467-023-36658-y","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhang J, Han B, et al. Noncanonical amino acids as doubly bio-orthogonal handles for one-pot preparation of protein multiconjugates. Nat Commun. 2023;14(1):974.","journal-title":"Nat Commun"},{"issue":"40","key":"1704_CR158","doi-asserted-by":"publisher","first-page":"16101","DOI":"10.1073\/pnas.1211023109","volume":"109","author":"JY Axup","year":"2012","unstructured":"Axup JY, Bajjuri KM, Ritland M, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109(40):16101\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1704_CR159","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/bc400505q","volume":"25","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Stefano JE, Manning C, Kyazike J, Chen B, Gianolio DA, et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug Chem. 2014;25(3):510\u201320.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"1704_CR160","doi-asserted-by":"publisher","first-page":"S1629","DOI":"10.1016\/j.jtho.2017.09.138","volume":"12","author":"Y Nakanishi","year":"2017","unstructured":"Nakanishi Y. Cytotoxic chemotherapy. J Thorac Oncol. 2017;12(11):S1629\u2013S1629.","journal-title":"J Thorac Oncol"},{"key":"1704_CR161","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejmech.2014.09.051","volume":"87","author":"R Kaur","year":"2014","unstructured":"Kaur R, Kaur G, Gill RK, Soni R, Bariwal J. Recent developments in tubulin polymerization inhibitors: an overview. Eur J Med Chem. 2014;87:89\u2013124.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"1704_CR162","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/jcm10061332","volume":"10","author":"HP Chang","year":"2021","unstructured":"Chang HP, Cheung YK, Shah DK. Whole-body pharmacokinetics and physiologically based pharmacokinetic Model for Monomethyl Auristatin E (MMAE). J Clin Med. 2021;10(6):1332.","journal-title":"J Clin Med"},{"issue":"2","key":"1704_CR163","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2011.03.017","volume":"307","author":"M Lopus","year":"2011","unstructured":"Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011;307(2):113\u20138.","journal-title":"Cancer Lett"},{"issue":"3","key":"1704_CR164","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1021\/acssynbio.3c00575","volume":"13","author":"Q Liu","year":"2024","unstructured":"Liu Q, Wang Y, Xia X, Li Z, Li Y, Shen Y, et al. Combinatorial biosynthesis of 3-O-Carbamoylmaytansinol by rational engineering of the tailoring steps of ansamitocins. Acs Synth Biol. 2024;13(3):721\u20137.","journal-title":"Acs Synth Biol"},{"issue":"3","key":"1704_CR165","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/psp4.12769","volume":"11","author":"C Pouzin","year":"2022","unstructured":"Pouzin C, Tod M, Chadjaa M, Fagniez N, Nguyen L. Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study. Cpt-Pharmacomet Syst. 2022;11(3):384\u201394.","journal-title":"Cpt-Pharmacomet Syst"},{"issue":"5","key":"1704_CR166","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","volume":"20","author":"K Cheung-Ong","year":"2013","unstructured":"Cheung-Ong K, Giaever G, Nislow C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 2013;20(5):648\u201359.","journal-title":"Chem Biol"},{"issue":"2","key":"1704_CR167","first-page":"33","volume":"1","author":"Y Fu","year":"2018","unstructured":"Fu Y, Ho M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antib Ther. 2018;1(2):33\u201343.","journal-title":"Antib Ther"},{"issue":"2","key":"1704_CR168","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1006\/jmbi.1996.0718","volume":"265","author":"RA Kumar","year":"1997","unstructured":"Kumar RA, Ikemoto N, Patel DJ. Solution structure of the calicheamicin gamma 1I-DNA complex. J Mol Biol. 1997;265(2):187\u2013201.","journal-title":"J Mol Biol"},{"issue":"8","key":"1704_CR169","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1021\/acs.joc.8b02876","volume":"84","author":"AC Tiberghien","year":"2019","unstructured":"Tiberghien AC, Howard PW, Goundry WRF, McCormick M, Parker JS. An alternative focus for route design for the synthesis of antibody-drug conjugate payloads. J Org Chem. 2019;84(8):4830\u20136.","journal-title":"J Org Chem"},{"key":"1704_CR170","doi-asserted-by":"publisher","unstructured":"Hartley JA, Flynn MJ, Bingham JP, Corbett S, Reinert H, Tiberghien A, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018;8(1):10479.\u00a0https:\/\/doi.org\/10.1038\/s41598-018-28533-4.","DOI":"10.1038\/s41598-018-28533-4"},{"issue":"8","key":"1704_CR171","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1535-7163.MCT-16-0825","volume":"16","author":"J Harper","year":"2017","unstructured":"Harper J, Lloyd C, Dimasi N, et al. Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody-drug conjugate targeting 5T4. Mol Cancer Ther. 2017;16(8):1576\u201387.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1704_CR172","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1021\/mp500781a","volume":"12","author":"RC Elgersma","year":"2015","unstructured":"Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, et al. Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting Antibody-drug conjugate SYD985. Mol Pharm. 2015;12(6):1813\u201335.","journal-title":"Mol Pharm"},{"issue":"8","key":"1704_CR173","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","volume":"26","author":"HP Yao","year":"2021","unstructured":"Yao HP, Zhao H, Hudson R, Tong XM, Wang MH. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov Today. 2021;26(8):1857\u201374.","journal-title":"Drug Discov Today"},{"key":"1704_CR174","doi-asserted-by":"publisher","first-page":"114304","DOI":"10.1016\/j.ejmech.2022.114304","volume":"236","author":"A Talukdar","year":"2022","unstructured":"Talukdar A, Kundu B, Sarkar D, Goon S, Mondal MA. Topoisomerase I inhibitors: challenges, progress and the road ahead. Eur J Med Chem. 2022;236:114304.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1704_CR175","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16(1):3.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1704_CR176","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12282-024-01550-0","volume":"31","author":"M Hattori","year":"2024","unstructured":"Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast Cancer. 2024;31(3):335\u20139.","journal-title":"Breast Cancer"},{"issue":"1","key":"1704_CR177","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","volume":"9","author":"Z Li","year":"2024","unstructured":"Li Z, Song Z, Hong W, Yang N, Wang Y, Jian H, et al. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, Phase 1\/2 study. Signal Transduct Target Ther. 2024;9(1):182.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1704_CR178","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3390\/ijms22063128","volume":"22","author":"I Jurado-Martin","year":"2021","unstructured":"Jurado-Martin I, Sainz-Mejias M, McClean S. Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci. 2021;22(6):3128.","journal-title":"Int J Mol Sci"},{"key":"1704_CR179","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-016-0236-7","volume":"9","author":"Z Tu","year":"2016","unstructured":"Tu Z, Xiao R, Xiong J, et al. CCR9 in cancer: oncogenic role and therapeutic targeting. J Hematol Oncol. 2016;9:10.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"1704_CR180","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78(16):1763\u20137.","journal-title":"Drugs"},{"issue":"16","key":"1704_CR181","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","volume":"113","author":"JE Weldon","year":"2009","unstructured":"Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood. 2009;113(16):3792\u2013800.","journal-title":"Blood"},{"issue":"22","key":"1704_CR182","doi-asserted-by":"publisher","first-page":"8065","DOI":"10.1039\/D0CS00215A","volume":"49","author":"Z Xie","year":"2020","unstructured":"Xie Z, Fan T, An J, Choi W, Duo Y, Ge Y, et al. Emerging combination strategies with phototherapy in cancer nanomedicine. Chem Soc Rev. 2020;49(22):8065\u201387.","journal-title":"Chem Soc Rev"},{"issue":"4","key":"1704_CR183","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/ph12040163","volume":"12","author":"L Larue","year":"2019","unstructured":"Larue L, Myrzakhmetov B, Ben-Mihoub A, Moussaron A, Thomas N, Arnoux P, et al. Fighting hypoxia to improve PDT. Pharmaceuticals (Basel). 2019;12(4):163.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"1704_CR184","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/ph17070932","volume":"17","author":"D Aebisher","year":"2024","unstructured":"Aebisher D, Serafin I, Batog-Szczech K, Dynarowicz K, Chodurek E, Kawczyk-Krupka A, et al. Photodynamic therapy in the treatment of cancer-the selection of synthetic photosensitizers. Pharmaceuticals (Basel). 2024;17(7):932.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"1704_CR185","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.biotechadv.2016.04.005","volume":"34","author":"A Patel","year":"2016","unstructured":"Patel A, Sant S. Hypoxic tumor microenvironment: opportunities to develop targeted therapies. Biotechnol Adv. 2016;34(5):803\u201312.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"1704_CR186","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41377-022-00780-1","volume":"11","author":"B Li","year":"2022","unstructured":"Li B, Lin L. Internal light source for deep photodynamic therapy. Light Sci Appl. 2022;11(1):85.","journal-title":"Light Sci Appl"},{"issue":"18","key":"1704_CR187","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/ijms20184344","volume":"20","author":"ES Kang","year":"2019","unstructured":"Kang ES, Lee TH, Liu Y, Han KH, Lee WK, Yoon I. Graphene oxide nanoparticles having long wavelength absorbing chlorins for highly-enhanced photodynamic therapy with reduced dark toxicity. Int J Mol Sci. 2019;20(18):4344.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1704_CR188","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/intimm\/dxaa037","volume":"33","author":"H Kobayashi","year":"2021","unstructured":"Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol. 2021;33(1):7\u201315.","journal-title":"Int Immunol"},{"key":"1704_CR189","doi-asserted-by":"publisher","first-page":"129348","DOI":"10.1016\/j.bmcl.2023.129348","volume":"91","author":"MG Brant","year":"2023","unstructured":"Brant MG, Garnett GAE, Guedia J, Lasalle M, Lawn S, Petersen ME, et al. Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates. Bioorg Med Chem Lett. 2023;91:129348.","journal-title":"Bioorg Med Chem Lett"},{"issue":"17","key":"1704_CR190","doi-asserted-by":"publisher","first-page":"15756","DOI":"10.1021\/acs.jmedchem.4c01384","volume":"67","author":"AM Patel","year":"2024","unstructured":"Patel AM, Willingham A, Cheng AC, Tomazela D, Bowman E, Kofman E, et al. Design and optimization of selectivity-tunable toll-like receptor 7\/8 agonists as novel antibody-drug conjugate payloads. J Med Chem. 2024;67(17):15756\u201379.","journal-title":"J Med Chem"},{"issue":"1","key":"1704_CR191","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2(1):18\u201333.","journal-title":"Nat Cancer"},{"issue":"6657","key":"1704_CR192","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1126\/science.adf8974","volume":"381","author":"B Liu","year":"2023","unstructured":"Liu B, Carlson RJ, Pires IS, Gentili M, Feng E, Hellier Q, et al. Human STING is a proton channel. Science. 2023;381(6657):508\u201314.","journal-title":"Science"},{"issue":"7","key":"1704_CR193","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1158\/1538-7445.AM2023-4423","volume":"83","author":"J Soomer-James","year":"2023","unstructured":"Soomer-James J, Damelin M, Malli N. XMT-2056, a HER2-targeted STING agonist antibody-drug conjugate, exhibits ADCC function that synergizes with STING pathway activation and contributes to anti-tumor responses. Can Res. 2023;83(7):4423.","journal-title":"Can Res"},{"key":"1704_CR194","doi-asserted-by":"publisher","first-page":"107341","DOI":"10.1016\/j.phrs.2024.107341","volume":"207","author":"C Li","year":"2024","unstructured":"Li C, Shi K, Zhao S, Liu J, Zhai Q, Hou X, et al. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: recent advances and future directions. Pharmacol Res. 2024;207:107341.","journal-title":"Pharmacol Res"},{"issue":"28","key":"1704_CR195","doi-asserted-by":"publisher","first-page":"11390","DOI":"10.1002\/anie.201914935","volume":"59","author":"C Lutz","year":"2020","unstructured":"Lutz C, Simon W, Werner-Simon S, Pahl A, Muller C. Total synthesis of alpha- and beta-Amanitin. Angew Chem Int Ed Engl. 2020;59(28):11390\u20133.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"1704_CR196","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vazquez","year":"2021","unstructured":"Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, Palfi A, et al. HDP-101, an Anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20(2):367\u201378.","journal-title":"Mol Cancer Ther"},{"key":"1704_CR197","doi-asserted-by":"publisher","unstructured":"Singh RK, Jones RJ, Shirazi F, Qin L, Zou J, Hong S, et al. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. Res Sq. 2024:rs.3.rs-3843028. https:\/\/doi.org\/10.21203\/rs.3.rs-3843028\/v1.","DOI":"10.21203\/rs.3.rs-3843028\/v1"},{"issue":"1","key":"1704_CR198","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1021\/acs.accounts.8b00537","volume":"52","author":"KC Nicolaou","year":"2019","unstructured":"Nicolaou KC, Rigol S. Total synthesis in search of potent antibody-drug conjugate payloads. From the fundamentals to the translational. Acc Chem Res. 2019;52(1):127\u201339.","journal-title":"Acc Chem Res."},{"issue":"12","key":"1704_CR199","doi-asserted-by":"publisher","first-page":"e202100689","DOI":"10.1002\/cbic.202100689","volume":"23","author":"A Negi","year":"2022","unstructured":"Negi A, Voisin-Chiret AS. Strategies to reduce the on-target platelet toxicity of Bcl-x inhibitors: PROTACs, SNIPERs and prodrug-based approaches. ChemBioChem. 2022;23(12):e202100689.","journal-title":"ChemBioChem"},{"issue":"2","key":"1704_CR200","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/pharmaceutics16020221","volume":"16","author":"Y Choi","year":"2024","unstructured":"Choi Y, Choi Y, Hong S. Recent technological and intellectual property trends in antibody-drug conjugate research. Pharmaceutics. 2024;16(2):221.","journal-title":"Pharmaceutics"},{"issue":"8","key":"1704_CR201","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discovery. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discovery"},{"issue":"17","key":"1704_CR202","doi-asserted-by":"publisher","first-page":"e202400109","DOI":"10.1002\/cmdc.202400109","volume":"19","author":"WG Dong","year":"2024","unstructured":"Dong WG, Wang WQ, Cao C. The evolution of antibody-drug conjugates: toward accurate DAR and multi-specificity. Chemmedche. 2024;19(17):e202400109.","journal-title":"Chemmedche"},{"issue":"13","key":"1704_CR203","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.3390\/ijms25136969","volume":"25","author":"AA Chis","year":"2024","unstructured":"Chis AA, Dobrea CM, Arseniu AM, et al. Antibody-drug conjugates-evolution and perspectives. Int J Mol Sci. 2024;25(13):6969.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1704_CR204","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.4155\/bio-2018-0259","volume":"11","author":"M Carrasco-Triguero","year":"2019","unstructured":"Carrasco-Triguero M, Dere RC, Milojic-Blair M, et al. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials. Bioanalysis. 2019;11(17):1555\u201368.","journal-title":"Bioanalysis"},{"issue":"2","key":"1704_CR205","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.xphs.2015.11.037","volume":"105","author":"PL Ross","year":"2016","unstructured":"Ross PL, Wolfe JL. Physical and chemical stability of antibody drug conjugates: current status. J Pharm Sci. 2016;105(2):391\u20137.","journal-title":"J Pharm Sci"},{"issue":"12","key":"1704_CR206","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1016\/j.xphs.2017.08.016","volume":"106","author":"SV Sule","year":"2017","unstructured":"Sule SV, Fernandez JE, Mecozzi VJ, et al. Assessing the impact of charge variants on stability and viscosity of a high concentration antibody formulation. J Pharm Sci. 2017;106(12):3507\u201314.","journal-title":"J Pharm Sci"},{"issue":"7","key":"1704_CR207","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1007\/s11095-013-1274-2","volume":"31","author":"J Guo","year":"2014","unstructured":"Guo J, Kumar S, Prashad A, Starkey J, Singh SK. Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol- maleimide chemistry. Pharm Res. 2014;31(7):1710\u201323.","journal-title":"Pharm Res"},{"key":"1704_CR208","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-62703-541-5_16","volume":"1045","author":"Y Chen","year":"2013","unstructured":"Chen Y. Drug-to-antibody ratio (DAR) by UV\/Vis spectroscopy. Methods Mol Biol. 2013;1045:267\u201373.","journal-title":"Methods Mol Biol"},{"issue":"16","key":"1704_CR209","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.4155\/bio-2016-0120","volume":"8","author":"L Grafmuller","year":"2016","unstructured":"Grafmuller L, Wei C, Ramanathan R, Barletta F, Steenwyk R, Tweed J. Unconjugated payload quantification and DAR characterization of antibody-drug conjugates using high-resolution MS. Bioanalysis. 2016;8(16):1663\u201378.","journal-title":"Bioanalysis"},{"issue":"3","key":"1704_CR210","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpha.2020.05.008","volume":"10","author":"X Zhu","year":"2020","unstructured":"Zhu X, Huo S, Xue C, An B, Qu J. Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. J Pharm Anal. 2020;10(3):209\u201320.","journal-title":"J Pharm Anal"},{"issue":"10","key":"1704_CR211","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1248\/cpb.c21-00258","volume":"69","author":"Y Matsuda","year":"2021","unstructured":"Matsuda Y, Mendelsohn BA. Recent advances in drug-antibody ratio determination of antibody-drug conjugates. Chem Pharm Bull (Tokyo). 2021;69(10):976\u201383.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"6","key":"1704_CR212","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490\u20136.","journal-title":"Clin Cancer Res"},{"key":"1704_CR213","doi-asserted-by":"publisher","first-page":"204062072311547","DOI":"10.1177\/20406207231154708","volume":"14","author":"M Swaminathan","year":"2023","unstructured":"Swaminathan M, Cortes JE. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol. 2023;14:20406207231154708.","journal-title":"Ther Adv Hematol"},{"issue":"9825","key":"1704_CR214","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"issue":"9","key":"1704_CR215","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34(9):972\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1704_CR216","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","volume":"34","author":"JA Pollard","year":"2016","unstructured":"Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, et al. CD33 Expression and its association with gemtuzumab ozogamicin response: results from the randomized phase iii children\u2019s oncology group trial AAML0531. J Clin Oncol. 2016;34(7):747\u201355.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1704_CR217","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","volume":"127","author":"G Olombel","year":"2016","unstructured":"Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157\u201360.","journal-title":"Blood"},{"issue":"20","key":"1704_CR218","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1182\/blood.2023022244","volume":"142","author":"C R\u00f6llig","year":"2023","unstructured":"R\u00f6llig C. Gemtuzumab ozogamicin in AML: the next chapter. Blood. 2023;142(20):1673\u20134.","journal-title":"Blood"},{"key":"1704_CR219","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","volume":"7","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24.","journal-title":"Biomark Res"},{"issue":"10","key":"1704_CR220","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1200\/JCO.23.00943","volume":"42","author":"NH Russell","year":"2024","unstructured":"Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol. 2024;42(10):1158\u201368.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1704_CR221","doi-asserted-by":"publisher","first-page":"E180","DOI":"10.1634\/theoncologist.2019-0098","volume":"24","author":"NC Richardson","year":"2019","unstructured":"Richardson NC, Kasamon YL, Chen HY, de Claro RA, Ye JJ, Blumenthal GM, et al. FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma. Oncologist. 2019;24(5):E180\u20137.","journal-title":"Oncologist"},{"issue":"1","key":"1704_CR222","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17474086.2019.1558399","volume":"12","author":"C Van Der Weyden","year":"2019","unstructured":"Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Rev Hematol. 2019;12(1):5\u201319.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"1704_CR223","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24964","volume":"93","author":"AC Xavier","year":"2018","unstructured":"Xavier AC, Epperla N, Taub JW, Costa LJ. Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. Am J Hematol. 2018;93(2):238\u201345.","journal-title":"Am J Hematol"},{"issue":"6","key":"1704_CR224","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1200\/JCO.23.01799","volume":"42","author":"KM Kelly","year":"2024","unstructured":"Kelly KM, Friedberg JW. Classic Hodgkin lymphoma in adolescents and young adults. J Clin Oncol. 2024;42(6):653\u201364.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1704_CR225","first-page":"327","volume":"41","author":"LM Fornecker","year":"2023","unstructured":"Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, et al. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized. Phase II Trial J Clin Oncol. 2023;41(2):327\u201335.","journal-title":"Phase II Trial J Clin Oncol"},{"issue":"3","key":"1704_CR226","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, Phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288\u201398.","journal-title":"Ann Oncol"},{"key":"1704_CR227","doi-asserted-by":"publisher","first-page":"1346001","DOI":"10.3389\/fimmu.2024.1346001","volume":"15","author":"W Liu","year":"2024","unstructured":"Liu W, Wu J, Ming X, Zhang Q, Zhou D, Zheng R, et al. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed\/refractory ALK+ ALCL. Front Immunol. 2024;15:1346001.","journal-title":"Front Immunol"},{"issue":"14","key":"1704_CR228","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","volume":"77","author":"YN Lamb","year":"2017","unstructured":"Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77(14):1603\u201310.","journal-title":"Drugs"},{"issue":"4","key":"1704_CR229","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40272-024-00634-w","volume":"26","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Inotuzumab ozogamicin: first pediatric approval. Paediatr Drugs. 2024;26(4):459\u201367.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"1704_CR230","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","volume":"8","author":"LL Metheny","year":"2024","unstructured":"Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, et al. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024;8(6):1384\u201391.","journal-title":"Blood Adv"},{"issue":"1","key":"1704_CR231","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-023-01444-2","volume":"16","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, et al. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023;16(1):44.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1704_CR232","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood.2023022822","volume":"143","author":"P Rousselot","year":"2024","unstructured":"Rousselot P. Old rivals become new friends. Blood. 2024;143(5):380\u20132.","journal-title":"Blood"},{"issue":"20","key":"1704_CR233","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","volume":"17","author":"RJ Kreitman","year":"2011","unstructured":"Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398\u2013405.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1704_CR234","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","volume":"15","author":"RF Alderson","year":"2009","unstructured":"Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res. 2009;15(3):832\u20139.","journal-title":"Clin Cancer Res"},{"key":"1704_CR235","unstructured":"US Food and Drug Administration. FDA Drug Shortages. Accessed January 11, 2023. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/dsp_ActiveIngredientDetails.cfm?AI=Moxetumomab+pasudotox-tdfk+%28Lumoxiti%29+Injection&st=d&tab=tabs-4&panels=0."},{"issue":"13","key":"1704_CR236","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. polatuzumab vedotin: first global approval. Drugs. 2019;79(13):1467\u201375.","journal-title":"Drugs"},{"issue":"24","key":"1704_CR237","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1158\/1078-0432.CCR-24-1729","volume":"30","author":"M Sarraf Yazdy","year":"2024","unstructured":"Sarraf Yazdy M, Kasamon YL, Gu W, Rodriguez LR, Jin S, Bhatnagar V, et al. FDA approval summary: polatuzumab vedotin in the first-line treatment of select large B-cell lymphomas. Clin Cancer Res. 2024;30(24):5521\u20136.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1704_CR238","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MCA Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a Phase 1 study. Lancet Oncol. 2015;16(6):704\u201315.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1704_CR239","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363.","journal-title":"N Engl J Med"},{"issue":"31","key":"1704_CR240","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trneny M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-Cell lymphoma. J Clin Oncol. 2017;35(31):3529\u201337.","journal-title":"J Clin Oncol"},{"key":"1704_CR241","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.ctrv.2024.102691","volume":"124","author":"J Munoz","year":"2024","unstructured":"Munoz J, Deshpande A, Rimsza L, Nowakowski GS, Kurzrock R. Navigating between Scylla and Charybdis: a roadmap to do better than Pola-RCHP in DLBCL. Cancer Treat Rev. 2024;124:102691.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"1704_CR242","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/ajh.27075","volume":"98","author":"M Tavakkoli","year":"2023","unstructured":"Tavakkoli M, Barta SK. 2024 Update: Advances in the risk stratification and management of large B-cell lymphoma. Am J Hematol. 2023;98(11):1791\u2013805.","journal-title":"Am J Hematol"},{"issue":"5","key":"1704_CR243","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cpt.2409","volume":"110","author":"G Ferron-Brady","year":"2021","unstructured":"Ferron-Brady G, Rathi C, Collins J, et al. Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2021;110(5):1282\u201392.","journal-title":"Clin Pharmacol Ther"},{"issue":"20","key":"1704_CR244","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128\u201338.","journal-title":"Blood"},{"issue":"2","key":"1704_CR245","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase 2 study. Lancet Oncol. 2020;21(2):207\u201321.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1704_CR246","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a Phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u201312.","journal-title":"Lancet Haematol"},{"issue":"2","key":"1704_CR247","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","volume":"30","author":"S Trudel","year":"2024","unstructured":"Trudel S, Mccurdy A, Louzada ML, Parkin S, White D, Chu MP, et al. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a Phase 1\/2 trial. Nat Med. 2024;30(2):543\u201351.","journal-title":"Nat Med"},{"issue":"14","key":"1704_CR248","doi-asserted-by":"publisher","first-page":"11829","DOI":"10.3390\/ijms241411829","volume":"24","author":"I Ntanasis-Stathopoulos","year":"2023","unstructured":"Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Roussou M, et al. Real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma. Int J Mol Sci. 2023;24(14):11829.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1704_CR249","first-page":"2337","volume":"109","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, et al. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and\/or refractory multiple myeloma. Haematologica. 2024;109(7):2337\u201340.","journal-title":"Haematologica"},{"issue":"10","key":"1704_CR250","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Loncastuximab Tesirine: First Approval. Drugs. 2021;81(10):1229\u201333.","journal-title":"Drugs"},{"issue":"10","key":"1704_CR251","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094\u2013105.","journal-title":"Blood"},{"issue":"23","key":"1704_CR252","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","volume":"25","author":"BS Kahl","year":"2019","unstructured":"Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, et al. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2019;25(23):6986\u201394.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1704_CR253","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, Phase 2 trial. Lancet Oncol. 2021;22(6):790\u2013800.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1704_CR254","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","volume":"59","author":"M Iqbal","year":"2024","unstructured":"Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, et al. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2024;59(2):211\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1704_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112612","volume":"138","author":"J Panaampon","year":"2024","unstructured":"Panaampon J, Sungwan P, Fujikawa S, Sampattavanich S, Jirawatnotai S, Okada S. Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms. Int Immunopharmacol. 2024;138: 112612.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1704_CR256","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"key":"1704_CR257","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijcard.2022.12.043","volume":"375","author":"M Zhao","year":"2023","unstructured":"Zhao M, Chen C, Zhang C, Xu X, Tian F, Wu B, et al. Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: Disproportionality analysis of the FDA adverse event reporting system. Int J Cardiol. 2023;375:87\u201393.","journal-title":"Int J Cardiol"},{"issue":"21","key":"1704_CR258","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.20.03398","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021;39(21):2375\u201385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1704_CR259","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-022-01587-z","volume":"25","author":"SL de Haas","year":"2023","unstructured":"de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, et al. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, Phase III study (KRISTINE). Breast Cancer Res. 2023;25(1):2.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1704_CR260","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1245\/s10434-023-14766-9","volume":"31","author":"MN Khattak","year":"2024","unstructured":"Khattak MN, Chichura AM, Lang JE. Adjuvant Trastuzumab emtansine versus paclitaxel and trastuzumab in stage I HER2-Positive Breast Cancer: The ATEMPT Trial. Ann Surg Oncol. 2024;31(3):1423\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1704_CR261","doi-asserted-by":"publisher","first-page":"1332539","DOI":"10.3389\/fphar.2023.1332539","volume":"14","author":"Y Liang","year":"2024","unstructured":"Liang Y, Zhang PR, Li F, Lai HY, Qi TT, Wang YX. Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer. Front Pharmacol. 2024;14:1332539.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1704_CR262","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80(5):501\u20138.","journal-title":"Drugs"},{"key":"1704_CR263","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.847835","volume":"9","author":"J Yu","year":"2022","unstructured":"Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci. 2022;9: 847835.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"1704_CR264","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","volume":"31","author":"A Yver","year":"2020","unstructured":"Yver A, Agatsuma T, Soria JC. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers. Ann Oncol. 2020;31(3):430\u20134.","journal-title":"Ann Oncol"},{"issue":"7","key":"1704_CR265","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"issue":"12","key":"1704_CR266","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"key":"1704_CR267","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.breast.2023.01.005","volume":"67","author":"I Schlam","year":"2023","unstructured":"Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023;67:116\u201323.","journal-title":"Breast"},{"issue":"4","key":"1704_CR268","first-page":"1671","volume":"12","author":"PJ Kaboli","year":"2022","unstructured":"Kaboli PJ, Shabani S, Sharma S, Nasr MP, Yamaguchi H, Hung MC. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12(4):1671\u201385.","journal-title":"Am J Cancer Res"},{"issue":"16","key":"1704_CR269","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"1","key":"1704_CR270","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","volume":"35","author":"BA McGregor","year":"2024","unstructured":"McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, et al. The Double Antibody Drug Conjugate (DAD) Phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol. 2024;35(1):91\u20137.","journal-title":"Ann Oncol"},{"issue":"5","key":"1704_CR271","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/14737140.2022.2069563","volume":"22","author":"CM Mantia","year":"2022","unstructured":"Mantia CM, Sonpavde G. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(5):449\u201355.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"1704_CR272","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-019-01241-7","volume":"80","author":"KS Hanna","year":"2020","unstructured":"Hanna KS. Clinical overview of enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. Drugs. 2020;80(1):1\u20137.","journal-title":"Drugs"},{"issue":"12","key":"1704_CR273","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"11","key":"1704_CR274","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the Phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34(11):1047\u201354.","journal-title":"Ann Oncol"},{"issue":"4","key":"1704_CR275","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.anl.2022.06.004","volume":"50","author":"G Omura","year":"2023","unstructured":"Omura G, Honma Y, Matsumoto Y, Shinozaki T, Itoyama M, Eguchi K, et al. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. Auris Nasus Larynx. 2023;50(4):641\u20135.","journal-title":"Auris Nasus Larynx"},{"key":"1704_CR276","unstructured":"Rakuten Medical IlluminoxTM. https:\/\/rakuten-med.com\/ us\/illuminox\/. Accessed 11 March 2025."},{"issue":"12","key":"1704_CR277","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/nm.2554","volume":"17","author":"M Mitsunaga","year":"2011","unstructured":"Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17(12):1685\u201391.","journal-title":"Nat Med"},{"issue":"11","key":"1704_CR278","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1021\/acscentsci.8b00565","volume":"4","author":"K Sato","year":"2018","unstructured":"Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, et al. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy. ACS Cent Sci. 2018;4(11):1559\u201369.","journal-title":"ACS Cent Sci"},{"issue":"12","key":"1704_CR279","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/hed.26885","volume":"43","author":"DM Cognetti","year":"2021","unstructured":"Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, et al. Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021;43(12):3875\u201387.","journal-title":"Head Neck"},{"issue":"8","key":"1704_CR280","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","volume":"52","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019;52(8):2332\u20139.","journal-title":"Acc Chem Res"},{"issue":"1","key":"1704_CR281","doi-asserted-by":"publisher","first-page":"1841393","DOI":"10.1080\/2162402X.2020.1841393","volume":"9","author":"LC Gomes-da-Silva","year":"2020","unstructured":"Gomes-da-Silva LC, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. Oncoimmunology. 2020;9(1):1841393.","journal-title":"Oncoimmunology"},{"key":"1704_CR282","doi-asserted-by":"publisher","unstructured":"Kharbanda, Mahima et al. \u201cEfficacy and safety of cetuximab sarotalocan in recurrent\/locally advanced head-and-neck cancer: a comprehensive review.\u201d International Journal of Molecular and Immuno Oncology 2024. https:\/\/doi.org\/10.25259\/ijmio_9_2024.","DOI":"10.25259\/ijmio_9_2024"},{"issue":"4","key":"1704_CR283","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.20114","volume":"61","author":"P Agostinis","year":"2011","unstructured":"Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250\u201381.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1704_CR284","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nrc1071","volume":"3","author":"DE Dolmans","year":"2003","unstructured":"Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380\u20137.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1704_CR285","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/ijms23031532","volume":"23","author":"S Dasari","year":"2022","unstructured":"Dasari S, Njiki S, Mbemi A, Yedjou CG, Tchounwou PB. Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int J Mol Sci. 2022;23(3):1532.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1704_CR286","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929\u201335.","journal-title":"Drugs"},{"issue":"24","key":"1704_CR287","first-page":"12929","volume":"24","author":"L Li","year":"2020","unstructured":"Li L, Xu MZ, Wang L, Jiang J, Dong LH, Chen F, et al. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery. Eur Rev Med Pharmacol Sci. 2020;24(24):12929\u201337.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"1704_CR288","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29(1):1335\u201344.","journal-title":"Drug Deliv"},{"issue":"4","key":"1704_CR289","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"YY Xu","year":"2021","unstructured":"Xu YY, Wang YK, Gong JF, Zhang XT, Peng Z, Sheng XA, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913\u201325.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1704_CR290","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/1078-0432.CCR-19-1635","volume":"26","author":"P Sharma","year":"2020","unstructured":"Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, et al. Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy. Clin Cancer Res. 2020;26(1):61\u201370.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1704_CR291","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43\u201351.","journal-title":"Clin Cancer Res"},{"key":"1704_CR292","doi-asserted-by":"publisher","unstructured":"Peng Z, Liu TS, Wei J, Wang AR, He YF, Yang LZ, et al. A Phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers. J Clin Oncol. 2020;38(15). https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4560.","DOI":"10.1200\/JCO.2020.38.15_suppl.4560"},{"issue":"18","key":"1704_CR293","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Tisotumab Vedotin: First Approval. Drugs. 2021;81(18):2141\u20137.","journal-title":"Drugs"},{"key":"1704_CR294","doi-asserted-by":"publisher","unstructured":"Alley SC, Harris JR, Cao A, Gresnigt-van den Heuvel E, Velayudhan J, Satijn D, et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro. Cancer Res. 2019;79(13). https:\/\/doi.org\/10.1158\/1538-7445.AM2019-221.","DOI":"10.1158\/1538-7445.AM2019-221"},{"key":"1704_CR295","doi-asserted-by":"publisher","first-page":"S1586","DOI":"10.1016\/j.annonc.2023.10.410","volume":"34","author":"K Fujiwara","year":"2023","unstructured":"Fujiwara K, Slomovitz BM, Martin AG, Kalbacher E, Bagameri A, Ghamande S, et al. InnovaTV 301\/ENGOT-cx12\/GOG-3057: A global, randomized, open-label, Phase III study of tisotumab vedotin vs investigator\u2019s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Ann Oncol. 2023;34:S1586\u2013S1586.","journal-title":"Ann Oncol"},{"issue":"1","key":"1704_CR296","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Martin A, Fujiwara K, Kalbacher E, Bagam\u00e9ri A, Ghamande S, et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. New Engl J Med. 2024;391(1):44\u201355.","journal-title":"New Engl J Med"},{"issue":"36","key":"1704_CR297","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote I, Van Nieuwenhuysen E, O\u2019Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 Study. J Clin Oncol. 2023;41(36):5536\u201349.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1704_CR298","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","volume":"83","author":"YA Heo","year":"2023","unstructured":"Heo YA. Mirvetuximab Soravtansine: first approval. Drugs. 2023;83(3):265\u201373.","journal-title":"Drugs"},{"issue":"4","key":"1704_CR299","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1634\/theoncologist.2018-0459","volume":"24","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Betella I, Martin LP, Moore KN. Is targeting the folate receptor in ovarian cancer coming of age? Oncologist. 2019;24(4):425\u20139.","journal-title":"Oncologist"},{"issue":"3","key":"1704_CR300","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/ijgc-2022-003701","volume":"33","author":"A Chelariu-Raicu","year":"2023","unstructured":"Chelariu-Raicu A, Mahner S, Moore KN, Lorusso D, Coleman RL. Integrating antibody drug conjugates in the management of gynecologic cancers. Int J Gynecol Cancer. 2023;33(3):420\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"1704_CR301","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al. Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436\u201345.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1704_CR302","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","volume":"34","author":"G Bogani","year":"2024","unstructured":"Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, et al. Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer. 2024;34(4):469\u201377.","journal-title":"Int J Gynecol Cancer"},{"issue":"32","key":"1704_CR303","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","volume":"20","author":"DM O'Malley","year":"2024","unstructured":"O\u2019Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, et al. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRalpha-high platinum-sensitive ovarian cancer. Future Oncol. 2024;20(32):2423\u201336.","journal-title":"Future Oncol"},{"issue":"19","key":"1704_CR304","first-page":"3835","volume":"29","author":"A Dilawari","year":"2023","unstructured":"Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, et al. FDA approval summary: Mirvetuximab Soravtansine-Gynx for FRalpha-Positive. Platinum-Resistant Ovarian Cancer Clin Cancer Res. 2023;29(19):3835\u201340.","journal-title":"Platinum-Resistant Ovarian Cancer Clin Cancer Res"},{"key":"1704_CR305","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","volume":"13","author":"W Dokter","year":"2014","unstructured":"Dokter W, Ubink R, van der Lee M, et al. Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther. 2014;13:2618\u201329.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1704_CR306","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/ijms20051115","volume":"20","author":"G Rinnerthaler","year":"2019","unstructured":"Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int J Mol Sci. 2019;20(5):1115.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1704_CR307","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.24.00529","volume":"43","author":"N Turner","year":"2025","unstructured":"Turner N, Saura C, Aftimos P, et al. Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open-label, randomized, Phase III Trial (TULIP). J Clin Oncol. 2025;43(5):513\u201323.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1704_CR308","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","volume":"15","author":"AC Phillips","year":"2016","unstructured":"Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;15(4):661\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1704_CR309","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman AB, Pugh SL, Wang TJC, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 2023;25(2):339\u201350.","journal-title":"Neuro Oncol"},{"key":"1704_CR310","doi-asserted-by":"crossref","unstructured":"Decary S, Berne PF, Nicolazzi C, et al. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Clin Cancer Res. 2020;26(24):6589\u201399.","DOI":"10.1158\/1078-0432.CCR-19-4051"},{"issue":"4","key":"1704_CR311","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","volume":"33","author":"A Gazzah","year":"2022","unstructured":"Gazzah A, Bedard PL, Hierro C, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022;33(4):416\u201325.","journal-title":"Ann Oncol"},{"key":"1704_CR312","doi-asserted-by":"publisher","unstructured":"Johnson ML, Chadjaa M, Yoruk S, Besse B. Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy. J Clin Oncol 2020;38:TPS9625-TPS9625. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS9625.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9625"},{"key":"1704_CR313","doi-asserted-by":"publisher","unstructured":"Besse B, Lo Russo G, Lena H, Nadal E, Cousin S, Kowalski D, et al. OAo8.o5 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LCo3 Trial J Thorac Oncol. 2024;19(10):S25\u2013S26. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.050.","DOI":"10.1016\/j.jtho.2024.09.050"},{"issue":"10","key":"1704_CR314","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.urolonc.2022.05.013","volume":"41","author":"C Chu","year":"2023","unstructured":"Chu C, Pietzak E. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue \u201cseminar: treatment advances and molecular biology insights in urothelial carcinoma.\u201d Urol Oncol. 2023;41(10):398\u2013409.","journal-title":"Urol Oncol"},{"key":"1704_CR315","doi-asserted-by":"publisher","unstructured":"Shore* N, Michael O\u2019Donnell, Thomas Keane, Jewett MAS, Kulkarni GS, Dickstein R, et al. PD03\u201302 Phase 3 results of Vicinium in bcg-unresponsive non-muscle invasive bladder cancer. J Urol. 2020;203(Supplement 4):e72. https:\/\/doi.org\/10.1097\/JU.0000000000000823.02.","DOI":"10.1097\/JU.0000000000000823.02"},{"issue":"11","key":"1704_CR316","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/acs.bioconjchem.3c00374","volume":"34","author":"JM Sasso","year":"2023","unstructured":"Sasso JM, Tenchov R, Bird R, Iyer KA, Ralhan K, Rodriguez Y, et al. The evolving landscape of antibody-drug conjugates: In depth analysis of recent research progress. Bioconjug Chem. 2023;34(11):1951\u20132000.","journal-title":"Bioconjug Chem."},{"issue":"11","key":"1704_CR317","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023;24(11):9674.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1704_CR318","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659\u201371.","journal-title":"MAbs"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01704-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:37:00Z","timestamp":1746506220000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01704-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":318,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01704-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}